Progen Pharmaceuticals Ltd (PGL) announced today that the company’s biopharmaceuticals manufacturing subsidiary PharmaSynth Pty Ltd, had secured a new contract with Zensun (Shanghai) Sci & Tech Co Ltd. Zensun has successfully developed two drugs: the Recombinant Human Neuregulin-1 (rhNRG-1) injection, an anti-heart failure drug, and Recombinant Human ErbB3 fragment injection, a therapeutic vaccine against tumours. Both have undergone clinical trials. PharmaSynth has been contracted to manufacture rhNRG-1 for a forthcoming US based phase II clinical trial. PharmaSynth has expertise in recombinant proteins, bacterial and viral vaccines, whole cell therapeutics and small molecule synthesis and has previously manufactured this product for use by Zensun.
PharmaSynth’s CEO Les Tillack said the securing of this new contract demonstrated PharmaSynth’s position as an important Australian based contract manufacturer operating in the global market. “The opportunity to manufacture rhNRG-1 is an exciting one for PharmaSynth. We consider it a privilege to be involved with the development project for such a promising new drug. This project fits well with our core skills in recombinant protein manufacture and demonstrates our abilities as a world class biopharmaceutical contract manufacturing organization,” he said. Progen CEO, Sue MacLeman confirmed PharmaSynth Pty Ltd continued to expand into the global biopharmaceutical manufacturing market through a commitment to quality pharmaceutical manufacturing and flexibile service provision.
Progen Pharmaceuticals Limited is a biotechnology company committed to the discovery, development and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has built a focus and strength in anti-cancer drug discovery and development. Progen targets the multiple mechanisms of cancer across its three technology platforms of angiogenesis, epigenetics and cell proliferation. Progen has operations in Australia and the United States of America. PharmaSynth is a Brisbane, Australia based, drug development and contract manufacturer serving the pharmaceutical, biotechnology and veterinary industries.
Zensun ( Shanghai ) Sci & Tech Co., Ltd. is a bio-tech pharmaceutical company well-versed in the demands of the international market with a high profit potential based on innovation. It is devoted to the research and development of new drugs through self-owned intellectual properties. With adherence to the tenet of “healing for life”, Zensun has long been focusing on the research of anti-tumor drugs and anti-heart failure drugs. Based on the innovative theory, Zensun has successfully developed two drugs: the Recombinant Human Neuregulin- 1 injection, an anti-heart failure drug, and Recombinant Human ErbB3 fragment injection, a therapeutic vaccine against tumors, both have undergone clinical trial. Zensun (Shanghai) Sci & Tech Co Ltd is based in the Peoples Republic of China.